Topics

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

00:23 EDT 16 Aug 2019 | SCRIP

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus...

      

Related Stories

 

Original Article: Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

NEXT ARTICLE

More From BioPortfolio on "Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...